Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptideCD30 is a potential therapeutic target in malignant mesotheliomaSelective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathwayAIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse modelInhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisonsA novel human dynactin-associated protein, dynAP, promotes activation of Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of human cancer cellsRb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazineHDAC2 regulates chromatin plasticity and enhances DNA vulnerabilityOncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathwayGenistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone functionSynergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesisSynergistic interaction of lovastatin and paclitaxel in human cancer cellsTopoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexesNeuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastomaA YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancersTwo types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapySorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cellsMechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastomaPaclitaxel-dependent cell lines reveal a novel drug activity.Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor targetA heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transferRadiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerPushing the envelope in the mTOR pathway: the second generation of inhibitorsMesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerA novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κBNVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomasEBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistanceS1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cellsQuantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fateTargeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activitySKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseA novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.Durability of Kinase-Directed Therapies--A Network Perspective on Response and ResistanceTumor-Related Molecular Mechanisms of Oxaliplatin Resistance
P1433
Q22241958-4BB0B2A4-3A42-4B47-95EB-AE1B302737E8Q23919167-CFEC4BE2-6CF9-44D1-8F04-EDD688F18E6AQ23921491-A8921A55-E20F-4863-8B25-AA26F6C3F3FDQ23924042-5990B408-A7E1-49B4-9657-A25EA4266826Q24301826-7BEE079C-9584-492D-A011-6EBF0AF36FDFQ24301844-32313A62-8CE8-4658-83BC-AA2214E60123Q24304405-A52994F0-952A-44FF-BE82-C55E913D3996Q24313552-B0D3A263-B373-4863-8917-6ADE42F16C56Q24316879-292F5881-2A84-4161-A4A7-FE75E663D9C1Q24322002-45FA4EEC-4130-47F3-97DB-75A3C40B02BDQ24322054-185348D7-3DCC-42C2-9CA5-FB2AE418A95DQ24323164-C1EB7343-DAD0-4E5B-B02F-357C1F553E56Q24323696-CD2D0067-2370-4B7C-9739-257C5D0944C0Q24337091-F7A1A2E6-F3D7-4C21-B7E4-C8DC9793001BQ24594695-5263564C-616D-4CCE-8416-3AC7B5EBB3C8Q24595527-66CDA588-B2A0-41E2-9396-7A1943F9BECFQ24598856-C6DF43A2-E436-4C14-8354-FF454CF3CF37Q24602021-788519F7-09E3-4E8E-ABBA-0CA745CBC681Q24607424-8FEFBBC4-7F6D-4F6A-919E-F5D4307BF87DQ24608070-F24AFFDE-5211-4E6A-AF3F-90E2388828E9Q24608574-9194F4E3-AEFC-47D7-AE67-B9E1B526526EQ24616181-4242B012-F0D7-490B-85A1-488E952E1C1BQ24616197-45FEB7B2-CDAB-401A-8A81-BB054A67BBEAQ24622222-DF0C790B-DCD9-4DCF-9845-32B0DBC5244DQ24622837-2F11CC0E-2357-4CF8-B74E-141DBF84731CQ24635114-BD161590-54D9-48B7-B185-5CB19A7D2323Q24646237-D23EC291-CEAD-4691-95DD-B1009D670AB7Q24646417-0B5D7F2C-3F59-4724-923B-3B865DB1937BQ24646539-4650ECE1-2E1E-47AC-B5DB-E7E0D327394AQ24648997-097F24A4-82CD-4F3C-8809-C67605E4C160Q24650655-6428D5C3-3C9B-41EE-9ABA-917CFAEE23C2Q24656966-112E388B-CEEC-4E1A-91AF-1E8EF4C3888CQ24657514-7B8F396C-7608-44F6-B2E4-1D816B421C04Q24791775-19AAA484-500F-47E5-8852-B54B119B0AEFQ24799458-5E74BE9B-0583-4793-B0D8-AD9146D4A9ADQ24812998-47CB28E2-CAF6-4A73-BEED-7F6AB41F7101Q24815528-29335FDD-AFDF-4E62-8BF8-AB8E965FB5B8Q25255636-83B3EF65-0D26-479C-A883-88D6E73B166AQ26799145-5C9B6848-5E30-4039-8C04-19B476309D98Q26799848-DE0B9F0E-A811-49AC-8C16-C6B2BDB283B4
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Molecular Cancer Therapeutics
@ast
Molecular Cancer Therapeutics
@da
Molecular Cancer Therapeutics
@de
Molecular Cancer Therapeutics
@en
Molecular Cancer Therapeutics
@es
Molecular Cancer Therapeutics
@fi
Molecular Cancer Therapeutics
@fo
Molecular Cancer Therapeutics
@fr
Molecular Cancer Therapeutics
@is
Molecular Cancer Therapeutics
@it
type
label
Molecular Cancer Therapeutics
@ast
Molecular Cancer Therapeutics
@da
Molecular Cancer Therapeutics
@de
Molecular Cancer Therapeutics
@en
Molecular Cancer Therapeutics
@es
Molecular Cancer Therapeutics
@fi
Molecular Cancer Therapeutics
@fo
Molecular Cancer Therapeutics
@fr
Molecular Cancer Therapeutics
@is
Molecular Cancer Therapeutics
@it
prefLabel
Molecular Cancer Therapeutics
@ast
Molecular Cancer Therapeutics
@da
Molecular Cancer Therapeutics
@de
Molecular Cancer Therapeutics
@en
Molecular Cancer Therapeutics
@es
Molecular Cancer Therapeutics
@fi
Molecular Cancer Therapeutics
@fo
Molecular Cancer Therapeutics
@fr
Molecular Cancer Therapeutics
@is
Molecular Cancer Therapeutics
@it
P3181
P1055
P1058
P1156
P1277
P1476
Molecular Cancer Therapeutics
@en
P236
P571
2001-01-01T00:00:00Z